Indolocarbazole derivatives – a promising class of anticancer drugs-Reference-Cited by-同舟云学术

Indolocarbazole derivatives – a promising class of anticancer drugs

Published:2019-01-11 Issue:4 Volume:17 Page:20-26
ISSN:1726-9784
Container-title:Russian Journal of Biotherapy
language:
Short-container-title:Rossijskij bioterapevtičeskij žurnal

Author:

Kiseleva M. P.¹,Pokrovsky V. S.²^ORCID,Tataskiy V. V.¹,Borisova L. M.¹,Golubeva I. S.¹,Ektova L. V.¹

Affiliation:

1. N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

2. N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; RUDN University

Abstract

The paper discusses the possible mechanisms of antitumor action of indolocarbazole derivatives. Here we present a data that show interaction drugs based on indolocarbazole derivatives with several intracellular targets and consequently activation different pathways of cell death. Also we present results of our studies on the mechanisms of antitumor action of compounds LCS-1006 and LCS-1208 synthesized in the N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia.

Publisher

Publishing House ABV Press

Reference52 articles.

1. Shtil A.A. Signal transduction pathways and transcriptional mechanisms as targets for prevention of emergence of multidrug resistance in human cancer cells (invited review). Current Drug Targets 2001;2:57–77. PMID: 11465539. DOI:10.2174/1389450013348957.

2. Blokhin D.Yu., Chmutin E.F., Ivanov P.K. Molekulyarnye misheni dlya protivoopukholevoi terapii: faktory rosta, angiogeneza, apoptoza. Rossiiskii bioterapevticheskii zhurnal 2011;10(3):25–30. [Blokhin D.Y., Chmutin E.F., Ivanov P.K. Molecular targets for anticancer therapy: growth factors, angiogenesis and apoptosis. Rossiyskiy bioterapevticheskiy zhurnal = Russian biotherapeutic journal 2011;10(3):25–30. (In Russ.)].

3. Blokhin D.Yu., Chmutin E.F., Ivanov P.K. Molekulyarnye misheni dlya protivoopukholevoi terapii: puti peredachi signala i epigeneticheskie modulyatory. Rossiiskii bioterapevticheskii zhurnal 2011;10(4):81–8. [Blokhin D.Y., Chmutin E.F., Ivanov P.K. Molecular targets for anticancer therapy: signaling pathways and epigenetic modulators. Rossiyskiy Bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2011;10(4):81–8. (In Russ.)].

4. Oh Y., Herbst R.S., Burris H. et al. Enzastaurin, an oral, serine/threonine kinase inhibitor, as second- or third-line therapy of non-small cell lung cancer. J Clin Oncol 2008;26(7):1135–41. PMID: 18309949. DOI: 10.1200/jco.2007.14.3685.

5. Rampling R., Sanson M., Gorlia T. et al. A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054). Neuro-Oncology 2012;14:344–50. PMID: 22291006. DOI: 10.1093/neuonc/nor221.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of Solid Dispersion Technology to Obtain a Model of Injectable Dosage Form of Indolocarbazole Derivative;Drug development & registration;2022-11-24

2. ANTITUMOR DRUGS BASED ON INDOLOCARBAZOL DERIVATIVES;Pharmacy & Pharmacology;2021-09-08

3. Development and validation of HPLC method for analysis of indolocarbazole derivative LCS-1269;Pharmacia;2021-05-18

4. ANTITUMOR ACTIVITY OF SOME DERIVATIVES OF INDOLO[2,3-A]CARBAZOLES N-GLYCOSIDES WITH XYLOSE CARBOHYDRATE RESIDUE;Russian Journal of Biotherapy;2020-12-09